Oliver S. Thomas

Amgen (Germany) — Germany

Medicine · Health Sciences

19h-index1.7kcitations79works1.32yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(41), Immune Cell Function and Interaction(30), Monoclonal and Polyclonal Antibodies Research(26), T-cell and B-cell Immunology(22), Cancer Immunotherapy and Biomarkers(20)

Publications79 total

Supplementary Video S1 UT from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2025Open Access

Supplementary Figures and Figure Legends from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2025Open Access

Supplementary Video S2 MMP14 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2025Open Access

Supplementary Table S1 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2025Open Access

Lamprey FOXN1 rescues the block of thymic epithelial cell development in the mouse Foxn1 -deficient thymic rudiment

Proceedings of the National Academy of Sciences·2025Open Access

Developmental trajectory and evolutionary origin of thymic mimetic cells

8 cited

Nature·2025· 8 citedOpen Access

How useful are 3-month repeat-dose toxicology studies for the development of T cell engagers for oncology indications?

1 cited

Regulatory Toxicology and Pharmacology·2025· 1 cited

Data from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 2 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Supplementary Table S1 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 2 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 7 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Supplementary Video S2 MMP14 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 4 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 3 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 7 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 6 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Supplementary Figures and Figure Legends from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 5 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

Figure 3 from Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands

2023Open Access

page 1 of 4Next →

Frequent Co-authors

Wilfried Weber(23), Susana Minguet(19), Katrin Raute(17), Juliane Strietz(16), María Alejandra Parigiani(15), Geoffroy Andrieux(15), Klaus M. Kistner(15), Marina Zintchenko(15), Peter Aichele(15), Maike Hofmann(15), Houjiang Zhou(15), Melanie Boerries(15), Mahima Swamy(15), Jochen Maurer(15), Benno Rattel(14), Joachim Wahl(11), Matthias Friedrich(9), Angela Coxon(9), Tobias Raum(7), Mercedesz Balázs(7)